Andexxa Will Be a New Reversal Agent for Bleeding Due to Eliquis or Xarelto

July 2018

You'll hear about a new IV med to reverse bleeding from apixaban or rivaroxaban called Andexxa (an-DEK-sah, inactivated recombinant factor Xa).

Until now, the only reversal agent for the direct oral anticoagulants was idarucizumab (Praxbind).

But it just reverses dabigatran (Pradaxa).

Practical advice for a better career, with unlimited access to CE

Hospital Pharmacy Technician's Letter includes:

12 issues every year, with brief articles about new meds and hot topics
120+ CE courses, including the popular CE-in-the-Letter
Helpful, in-depth Technician Tutorials
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

Practice Decipher Unclear Expiration and Beyond-Use Dates
Anticoagulants Andexxa Will Be a New Reversal Agent for Bleeding Due to Eliquis or Xarelto
Medication Errors Use Strategies to Prevent Common Med Errors in Newborns
Neurology & Pain Avoid Mix-Ups Between Clorotekal and Other Chloroprocaine Products
Critical Care Have IV Lipids On Hand for Patients With Toxicity From Local Anesthetics
Gastroenterology Ensure Patients With Variceal Bleeding Get the Right Meds
Practice Help Facilitate IV-to-PO Switches
Communication Improve Communication With Older Patients
Respiratory & Allergy Prevent Mix-Ups With Xhance, a New Fluticasone Spray for Nasal Polyps
Crohn Disease Expect More Crohn's Patients to Get Biologics